Trump health pick Alex Azar testifies at Senate confirmation hearing - (CNBC via NewsPoints Desk)

  • Alex Azar, who has been nominated by US President Donald Trump to head the Department of Health and Human Services, agreed that "drug prices are too high" under questioning during a Senate confirmation hearing, CNBC reported Tuesday.

  • During the hearing, Democratic senators grilled Azar on his role in price increases during his time as president of Eli Lilly's US operations.

  • "We can do things together," Azar commented, adding "no one company's going to fix this system."

  • Azar also expressed willingness to consider whether Medicare Part B should have the ability to negotiate drug prices similarly as Medicare Part D.

  • Azar has been nominated to replace Tom Price, who resigned last September following scrutiny over his use of private aircraft for government travel.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.